Tag: role

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

ROHM’s SiC MOSFET Adopted in BBU for AI Servers as HVDC Architectures Advance

KYOTO, Japan, June 8, 2026 /PRNewswire/ -- ROHM Co., Ltd. has announced that its 750V SiC MOSFET has been adopted in a BBU (Battery Backup...

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales

Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...

Expanding its partnership with non-profits, EZVIZ upgrades its Green Initiative to make a true impact on harmony between humans and nature with a week-long...

HOOFDDORP, Netherlands, June 8, 2026 /PRNewswire/ -- EZVIZ, a world-leading smart home brand, announced to enter a new chapter of its EZVIZ Green Initiative by expanding...

Vi Appoints Spencer Honeyman as President, Global Growth

NEW YORK, June 7, 2026 /PRNewswire/ -- Vi today announced the promotion of Spencer Honeyman to President, Global Growth. ...

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

Enabled Talent launches One Company. One Talent, inviting Canadian employers to create one inclusive opportunity and build a stronger workforce.

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

IBA‑UIBC Cup of Bakers 2027 “Golden Statue Cup” China Selection – Hong Kong & Macao SAR Selection Competition Successfully Held in Hong Kong

Competition Highlights Industry Excellence and Strengthens International Exchange in the Baking Sector HONG KONG, June 7, 2026 /PRNewswire/ -- The Final of the IBA‑UIBC Cup...

Vision Insurance After Retirement (2026): VSP Vision Care Named Leading Option for Retiree Eye Coverage by Expert Consumers

NEW YORK, June 7, 2026 /PRNewswire/ -- A recent analysis from Expert Consumers highlights VSP® Vision Care as a leading option for vision insurance...

The Adam Foundation Commits $750,000 to the FIFA Global Citizen Education Fund, Helping Drive the Initiative Past the $50 Million Mark

Announcement made at Global Citizen Live: Rio de Janeiro ahead of the FIFA World Cup FinalLONDON, June 7, 2026 /PRNewswire/ -- The Adam Foundation,...

University of Phoenix researchers publish study examining doctoral students’ attitudes toward AI chatbots and ChatGPT use in higher education

Peer-reviewed study by Center for Educational and Instructional Technology Research team highlights connections between student perceptions of AI, academic integrity concerns and reported chatbot...

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsRole

DCH Motors Rebrands as DCH Mobility, Signalling Strategic Shift towards a Smart Mobility Ecosystem

Pony AI Inc. Announces Results of the Annual General Meeting

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress